Shares of Bionano Genomics(NASDAQ: BNGO)were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.
Full Answer
Is bngo stock really down 47% this year?
Source: Natali_ Mis/ShutterStock.com However, at this point, BNGO stock is down 47% from its close of $6.12 on Nov. 3. It’s down 55% since the start of the year. And if you look at its all-time high close of $15.57 on February 16, BNGO stock has dropped 79%. So why are investment analysts sin
Why is bngo stock on a wild ride?
Alongside the real-world progress, BNGO stock has been on a wild ride. The shares soared to improbable heights at the start of year, but have been on a downtrend since and now sit 80% below the February highs. That said, Oppenheimer’s Kevin DeGeeter believes that behind the volatility lies an “undera
How can I get the latest news and ratings for bngo?
Sign up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Is bngo a sell or buy on Robinhood?
Today BNGO ranks #8467 as sell candidate. Get a Free Stock at Robinhood Which way will BNGO go? Request * StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
See more
Is BNGO a good stock to buy now?
Right now, BNGO stock trades at around the same price as it did before its massive break out to begin 2021. In turn, with this incredible performance last year and its massive potential in genomic analysis, it could be a multi-bagger in the future.
Will BNGO stock go back up?
Based on our forecasts, a long-term increase is expected, the "BNGO" stock price prognosis for 2027-06-04 is 5.820 USD. With a 5-year investment, the revenue is expected to be around +323.29%. Your current $100 investment may be up to $423.29 in 2027. Get It Now!
Is BNGO a pump and dump?
BNGO stock has suffered at the hands of a Ritalin-using pump and dump scheme making waves in 2021.
Does BNGO have FDA approval?
It might be a year before we see $12.... yes, yes I know that BNGO does not need FDA approval to make money...but once FDA approval is established BNGO will be in every hospital in the USA within 2 years.... Every medical insurance company will be wanting everyone to use this technology.
Is BNGO stock a buy or sell?
The last rating was given by BTIG on Apr 07, 2022. The price target was changed from 2.32 to 3.73. Over the last 90 days, this security got 0 buy, 1 sell, and 0 hold ratings....Predicted Opening Price for BioNano Genomics Inc. of Monday, June 6, 2022.Fair opening price June 6, 2022Current price$1.67$1.66 (Undervalued)
Is BNGO a Buy Sell or Hold?
Bionano Genomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Is BNGO a meme stock?
Admittedly, it has been a while since Bionano Genomics (NASDAQ:BNGO) stock has been a “hot stock,” a “meme stock” or whatever you want to call it.
Does Ark hold BNGO?
At this time, ARK does not invest in BNGO. With that said, the company does appear to have some promise in its own right. Like all speculative small-cap companies, Bionano Genomics is a risky stock to own.
What is BNGO price target?
Stock Price Target BNGOHigh$12.00Median$8.00Low$6.00Average$8.67Current Price$1.75
Is BioNano genomics profitable?
Bionano Genomics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth.
Who are BioNano genomics competitors?
BioNano Genomics's top competitors include BaseHealth, Predicine, Mammoth Biosciences and SiDx. BioNano Genomics develops nanoscale imaging and analytic platforms designed to analyze DNA and other genome-related peptides and proteins.
When did BioNano genomics go public?
SAN DIEGO, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.
Bionano Stock Looks to Have a Monster Comeback in Its Future
Bionano (NASDAQ:BNGO) stock has tumbled, but it will come back big. Source: Dennis Diatel / Shutterstock.com As Cathie Wood and many others know, owning growth stocks over the last year has not been easy.
Bionano Is Not the Genomics Stock To Bet On
Life sciences equipment manufacturer Bionano Genomics (NASDAQ:BNGO) was a popular meme stock last year. Consequently, its management raised a massive amount of cash through equity offerings. However, it has failed to sustain investor interest, as its flagship optimal genome mapping tool Saphyr hasn’t gained much traction in the medical community.
Bionano Genomics Is Interesting as Genome Testing Scales Upwards
Investors seeking a potentially explosive play in the growing genomic mapping sector ought to consider Bionano Genomics (NASDAQ:BNGO) stock. Source: Connect world / Shutterstock.com Readers are generally aware that scientific advancements are making it more possible to understand the genetic information inside each individual.
New Developments Bode Well for Bionano Stock, Says Analyst
This time last year, shares of Bionano Genomics (BNGO) were in the midst of one almighty tear, as the market seized upon the opportunity of its optical genome mapping (OGM) system Saphyr to disrupt the cytogenetics space.
Bionano Genomics Preliminary Q4, FY21 Revenue Exceed Expectations
Bionano Genomics Inc (NASDAQ: BNGO) posted preliminary Q4 sales of $5.8 million - $6.2 million, +25% - 33% sequentially, up 45% - 55% Y/Y, and above the consensus of $5.44 million. FY21 revenue is expected to be $17.5 million - $17.9 million (consensus $17.13 million), more than doubled from FY20.
Bionano Genomics Stock Is a Low-Priced Bet on Sound Science
For folks with a tolerance for risk, life sciences company Bionano Genomics (NASDAQ:BNGO) is definitely worth a look. It takes guts to invest in out-of-favor assets like BNGO stock, but the long-term rewards could be substantial. Source: Dennis Diatel / Shutterstock.com Just to recap, Bionano Genomics focuses on advancing genome mapping technology.
Bionano Genomics to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 1st, 2022
SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 1st, 2022 at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2021 and to highlight recent corporate progress.
Bionano Genomics Announces Publication of Prospective Study Demonstrating Performance Improvements from OGM in the Analysis of AML and MDS Compared to Traditional Methods
SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.
Bionano Stock Looks to Have a Monster Comeback in Its Future
Bionano (NASDAQ:BNGO) stock has tumbled, but it will come back big. Source: Dennis Diatel / Shutterstock.com As Cathie Wood and many others know, owning growth stocks over the last year has not been easy.
Bionano Genomics Appoints Helene Klein as its First Ever Chief People Officer
SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.
Bionano Genomics Announces First Publication Demonstrating OGM as an Alternative to Karyotyping for Product of Conception Sample Analysis
The newly proposed workflow has 93% success rate compared to 9.6% success rate of traditional methods by eliminating cell culture, replacing karyotyping analysis with OGM for comprehensive SV analysis of fetal tissue and adding chromosomal microarray analysis of formalin-fixed, paraffin-embedded POC tissue to recover samples contaminated with maternal cells.SAN DIEGO, Feb.
Bionano Genomics to Present at the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.
Bionano Is Not the Genomics Stock To Bet On
Life sciences equipment manufacturer Bionano Genomics (NASDAQ:BNGO) was a popular meme stock last year. Consequently, its management raised a massive amount of cash through equity offerings. However, it has failed to sustain investor interest, as its flagship optimal genome mapping tool Saphyr hasn’t gained much traction in the medical community.
Second Quarter 2021 Financial Results
BNGO stock suffered a $0.06 per share quarterly loss in the reported quarter. This is above than Zacks Consensus Estimate of loss of $0.05 per share.
Balance Sheet of BNGO stock
At the end of June 30, 2021, BNGO stock reported $333 million in cash and cash equivalents. These were $38.4 million by the end of December 2020. The equity raise completed in January 2021 is the main reason behind this increase.
Upcoming Milestones of BNGO stock
Bionano stock expects Commercial release of prenatal assays in the third quarter of 2021. pediatric assays menu expansion is also anticipated in the third quarter.
Conclusion
BNGO stock is falling despite increased revenue in second-quarter 2021 as compared to the same prior-year quarter. However, one thing is to note that its earnings surprise is -20% and quarterly loss is above the Zacks Consensus Estimate. The stock is progressing with time and continuing to conduct clinical studies which is a good sign.
The Reddit Effect Strikes Again
One of the big news stories of 2021 has been the Reddit effect. Retail investors have been using the platform to drive up the prices of many stocks that were previously struggling and attracting short-sellers.
Bottom Line on BNGO Stock
BioNano doesn’t get the degree of analyst coverage that headline-grabbing biotech companies have over the past year. CNN Money is following just four investment analysts that cover BNGO stock.
